Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service

Gossamer Bio Announces Data Presentations at the American Heart Association Scientific Sessions 2019


Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB002, the Company's inhaled PDGFR inhibitor for the treatment of pulmonary arterial hypertension (PAH), have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2019 being held November 16- 18 in Philadelphia, Pennsylvania.

Details for the AHA presentations are as follows:

Session Type: Abstract Rapid Fire Oral
Session Title: Novel Experimental Therapies for Pulmonary Arterial Hypertension
Session Date and Time: Sunday, November 17, 2019; 10:30- 11:20 a.m. ET
Abstract Control Number: 12947
Abstract Title: In Vivo Efficacy of a Novel, Inhaled PDGFRa/b Inhibitor, GB002, In The Rat Monocrotaline and Pneumonectomy Model of Pulmonary Arterial Hypertension
Presenter Name: Larry Zisman, MD, FACC
Presentation Date/Time: Sunday, November 17, 2019; 10:50- 10:55 a.m. ET
Presentation Number: RF272
Location: Zone 4, Science and Technology Hall, Level 2, Halls A-D

Session Type: Moderated Digital Poster Session
Session Title: Pathophysiology of RV Failure, HFpEF and PAH
Session Date and Time: Monday, November 18, 2019; 2:05- 2:55 p.m. ET
Abstract Control Number: 11102
Abstract Title: GB002, A Novel Inhaled PDGFR Kinase Inhibitor, Demonstrates Efficacy in The Su5416 Hypoxia Rat Model Of Pulmonary Arterial Hypertension (PAH)
Presenter Name: Anna Galkin, PhD
Presentation Date/Time: Monday, November 18, 2019; 2:35- 2:40 p.m. ET
Presentation Number: MDP428
Location: Moderated Posters 2, Science and Technology Hall, Level 2, Halls A-D

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.


These press releases may also interest you

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the second interim analysis of the Phase IIIb STASEY study, which reinforce the safety profile of Hemlibra® (emicizumab-kxwh) characterized in the Phase...

at 00:05
McKay Brothers International (MBI) announced expansion of its lowest known latency private bandwidth services to Busan. The company launched hybrid microwave/fiber private bandwidth services between Illinois and Busan as well as between Tokyo and...

at 00:00
Frontline Systems has released major new versions of both Analytic Solver®, its toolset for Excel for the Web, Windows and Macintosh, and RASON®, its cloud service on Azure, that enable companies to easily embed 'decision intelligence' in activities...

12 jui 2020
Global premier mobile phone brand TECNO Mobile (www.TECNO-Mobile.com) announced its newest smart phone Pouvoir 4 as an early adopter of the operating system upgrading to Android 11 beta 1 starting from July 10th . As part of the Android 11 Developer...

12 jui 2020
Rigaku Corporation is pleased to announce the introduction of the new Rigaku ZSX Primus IVi tube-below sequential wavelength dispersive X-ray fluorescence (WDXRF) spectrometer. WDXRF analyzers are known for high sensitivity and spectral resolution,...



News published on 11 november 2019 at 07:05 and distributed by: